GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California. Show more

Location: 1525 O’Brien Drive, Menlo Park, CA, 94025, United States | Website: https://grail.com | Industry: Diagnostics & Research | Sector: Healthcare


Market Cap

3.936B

52 Wk Range

$16.10 - $115.76

Previous Close

$100.98

Open

$102.16

Volume

287,644

Day Range

$98.55 - $103.23

Enterprise Value

3.455B

Cash

540.1M

Avg Qtr Burn

-82.18M

Insider Ownership

10.31%

Institutional Own.

65.19%

Qtr Updated

09/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date